Ireland
--:--IST
Recruiting Observational

Prediction of Long-term Outcome in Aortic Stenosis After Valve Intervention

NCT05629104 · tracked via the Priya Life Science Sweden tracker
Phase
Observational
Started
2019-05-15
Last updated
2022-11-29

Condition(s) studied

Aortic Stenosis

Investigational drug(s) / intervention(s)

There is no intervention since it is an observational study patients are treated according to clinical praxis

There is no intervention since it is an observational study patients are treated according to clinical praxis: No intervention

Study summary

Patients with severe aortic stenosis accepted for transcatheter intervention or open surgery are included before the intervention, and then followed up with clinical visits during the first year after intervention. Imaging with echocardiography and computed tomography (CT) are performed together with additional imaging with magnetic resonance imaging (MRI) and Positron emissions tomography (PET)-CT in a subgroup of the study population. Blood samples, physical performance and questionnaires with focus on frailty and heart failure are also collected at each visit. A follow up with information of the outcomes after 2-5 years will be performed through national registries.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Accepted for aortic valve intervention Exclusion Criteria: * No able to follow the study protocol

Primary outcome measure(s)

  • Semiquantitative assessment of protein levels associated with myocardial performance — One year after intervention.
    Level of normalized protein expression (NPX) in plasma, assessed by a multiplex proximity extension assay panel (Olink Bioscience, Uppsala, Sweden).
  • Imaging parameters associated with clinical outcome after intervention — One year after intervention
    Global longitudinal strain (%) of the right and left ventricle. The clinical outcome defined as a combination of mortality and hospitalization of heart failure
  • Semiquantitative assessment of protein levels associated with myocardial performance associated with clinical outcome after intervention — Two years after intervention
    Level of normalized protein expression (NPX) in plasma, assessed by a multiplex proximity extension assay panel (Olink Bioscience, Uppsala, Sweden). The clinical outcome defined as a combination of mortality and hospitalization for heart failure.

Trial sites (1)

FacilityCityRegionStatus
Department of cardiology Uppsala University Hospital Uppsala Sweden Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05629104 on ClinicalTrials.gov ↗ ← All trials in Sweden